{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:42:37Z","timestamp":1773477757948,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.114197","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:13:38Z","timestamp":1719533618000},"page":"114197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial"],"prefix":"10.1016","volume":"211","author":[{"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Malone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Y.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114197_bib1","article-title":"Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: secondary analysis of the LATITUDE study","author":"Roy","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114197_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jcpt.13092","article-title":"The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone\/enzalutamide: a systematic review and meta-analysis","volume":"45","author":"Yang","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.114197_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10552-015-0687-0","article-title":"Metformin and prostate cancer mortality: a meta-analysis","volume":"27","author":"Stopsack","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejca.2024.114197_bib4","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.5489\/cuaj.267","article-title":"Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study","volume":"7","author":"Niraula","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2024.114197_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114197_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2022.03.042","article-title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302","volume":"170","author":"Wilson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114197_bib7","article-title":"The multiple effects of aspirin in prostate cancer patients","volume":"26","author":"Joshi","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ejca.2024.114197_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-018-0318-7","article-title":"Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies","volume":"18","author":"Cao","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.ejca.2024.114197_bib9","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.18632\/oncotarget.6837","article-title":"Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer?","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2024.114197_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcp.13425","article-title":"Drug\u2013drug interaction potential in men treated with enzalutamide: Mind the gap","volume":"84","author":"Benoist","year":"2018","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.ejca.2024.114197_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/17425255.2022.2122812","article-title":"Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions","volume":"18","author":"Conde-Est\u00e9vez","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejca.2024.114197_bib12","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2024.114197_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2024.114197_bib14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114197_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/path.1529","article-title":"Linkage of angiotensin I-converting enzyme gene insertion\/deletion polymorphism to the progression of human prostate cancer","volume":"202","author":"Medeiros","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2024.114197_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41391-020-0248-9","article-title":"The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study","volume":"23","author":"Goldberg","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2024.114197_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/pros.24274","article-title":"Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer","volume":"82","author":"Nakayama","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2024.114197_bib18","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.18632\/oncotarget.6837","article-title":"Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer?","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2024.114197_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.664741","article-title":"Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment\u2014a cardio-oncology study","volume":"11","author":"Wilk","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114197_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5414\/CP204198","article-title":"Drug-drug interaction between apalutamide and atorvastatin through breast cancer resistance protein in an outpatient","volume":"60","author":"Watanabe","year":"2022","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.114197_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/biomedicines11010029","article-title":"Long-term treatment with simvastatin leads to reduced migration capacity of prostate cancer cells","volume":"11","author":"Kafka","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2024.114197_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2024.114197_bib23","article-title":"Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials","author":"Fukuokaya","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2024.114197_bib24","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/EDE.0000000000000752","article-title":"R function for additive interaction measures","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2024.114197_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/aje\/kwn411","article-title":"Estimation of the relative excess risk due to interaction and associated confidence bounds","volume":"169","author":"Richardson","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejca.2024.114197_bib26","first-page":"33","article-title":"A tutorial on interaction","volume":"3","author":"Van Der Weele","year":"2014","journal-title":"Epidemiol Methods"},{"key":"10.1016\/j.ejca.2024.114197_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10654-011-9554-9","article-title":"Estimating measures of interaction on an additive scale for preventive exposures","volume":"26","author":"Knol","year":"2011","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejca.2024.114197_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2307\/2530904","article-title":"Confidence intervals for the survival function using cox\u2019s proportional- hazard model with covariates","volume":"40","author":"Link","year":"1984","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2024.114197_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00985768","article-title":"Product-limit survival functions with correlated survival times","volume":"1","author":"Williams","year":"1995","journal-title":"Lifetime Data Anal"},{"key":"10.1016\/j.ejca.2024.114197_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/15384047.2016.1156273","article-title":"Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression","volume":"17","author":"Chen","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2024.114197_bib31","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Sahra","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejca.2024.114197_bib32","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T19:43:57Z","timestamp":1728071037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":32,"alternative-id":["S0959804924008530"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114197","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114197"}}